Can Bifidobacterium bifidum improve intestinal microbiota in premature infants?
Views : 2
Update time : 2026-04-21 10:07:56
Bifidobacterium bifidum is the earliest discovered species in the Bifidobacterium genus. It is a Gram-positive obligate anaerobe, non-motile and non-spore-forming. As the primary colonizer of the infant gut, it metabolizes carbohydrates such as lactose and oligosaccharides to produce acetic acid and lactic acid. These substances not only supply direct energy for infants but also maintain an acidic intestinal environment and act as a critical barrier against harmful bacteria. Approved for infant formula and clinical adjuvant therapy in many countries worldwide, it has demonstrated long-term safety and clinical efficacy in routine use within global Neonatal Intensive Care Units (NICUs).
In practical applications, Bifidobacterium bifidum is widely used in infant formula milk powder, dietary supplements and clinical nutrition due to its multiple benefits including anti-allergy, anti-inflammation and immune regulation. Its major applications include: preventing and alleviating antibiotic-associated diarrhea and necrotizing enterocolitis (NEC), strengthening intestinal barrier function and immunity in newborns (especially cesarean-born and premature infants), reducing risks of atopic dermatitis and food allergies, as well as relieving functional constipation and indigestion.
So can Bifidobacterium bifidum actually optimize intestinal microbiota in premature infants? Clinical evidence provides a clear and conclusive answer.
2025 RCT (68 premature infants): Intervention with Bifidobacterium bifidum + Lactobacillus acidophilus (BB/LA) significantly improved gut microbial beta diversity, elevated abundances of Bifidobacteria and Lactobacilli, reduced pathogenic Clostridium, with no adverse events reported.
2025 Meta-analysis (7,180 premature infants): Strain G001 (BBG001) reduced NEC risk by 34%, sepsis risk by 29%, and infection-related mortality risk by 20%.
2024 RCT for cesarean newborns: 6-month supplementation of Bifidobacterium bifidum lowered gut dysbiosis risk, with effects lasting up to 12 months.
Multiple systematic reviews consistently confirm that probiotic supplementation is safe for premature infants and delivers clinically significant benefits. Multi-strain formulas perform better, particularly in NEC prevention and feeding outcome improvement, highlighting the vital role of precise strain selection in maximizing therapeutic effects.
In practical applications, Bifidobacterium bifidum is widely used in infant formula milk powder, dietary supplements and clinical nutrition due to its multiple benefits including anti-allergy, anti-inflammation and immune regulation. Its major applications include: preventing and alleviating antibiotic-associated diarrhea and necrotizing enterocolitis (NEC), strengthening intestinal barrier function and immunity in newborns (especially cesarean-born and premature infants), reducing risks of atopic dermatitis and food allergies, as well as relieving functional constipation and indigestion.
So can Bifidobacterium bifidum actually optimize intestinal microbiota in premature infants? Clinical evidence provides a clear and conclusive answer.
2025 RCT (68 premature infants): Intervention with Bifidobacterium bifidum + Lactobacillus acidophilus (BB/LA) significantly improved gut microbial beta diversity, elevated abundances of Bifidobacteria and Lactobacilli, reduced pathogenic Clostridium, with no adverse events reported.
2025 Meta-analysis (7,180 premature infants): Strain G001 (BBG001) reduced NEC risk by 34%, sepsis risk by 29%, and infection-related mortality risk by 20%.
2024 RCT for cesarean newborns: 6-month supplementation of Bifidobacterium bifidum lowered gut dysbiosis risk, with effects lasting up to 12 months.
Multiple systematic reviews consistently confirm that probiotic supplementation is safe for premature infants and delivers clinically significant benefits. Multi-strain formulas perform better, particularly in NEC prevention and feeding outcome improvement, highlighting the vital role of precise strain selection in maximizing therapeutic effects.
